Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ebola Zaire vaccine (live, attenuated)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ebola Zaire vaccine (live, attenuated) is a recombinant, replication-competent viral vector vaccine used for the prevention of disease caused by the Zaire ebolavirus. The most widely used formulation is based on a live, attenuated vesicular stomatitis virus (VSV) that has been genetically engineered to express the main glycoprotein from the Zaire ebolavirus. This modification provokes a strong neutralizing immune response against the Ebola virus. The primary mechanism of action involves induction of both cellular and humoral immunity to protect against future infection with Zaire ebolavirus. The first-generation product was developed by scientists at Canada’s National Microbiology Laboratory and later licensed to Newlink Genetics and then Merck for further development and commercialization as Ervebo. It is approved in multiple regions including the US and EU for use in adults and children 12 months or older[1][3][8].
- Brand names
- ErveboZabdeno
- Other names
- Ebola Zaire vaccine liveRecombinant vesicular stomatitis virus–Zaire Ebola virus vaccine
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Ebola Zaire vaccine (live, attenuated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ebola Zaire vaccine (live, attenuated).